- Home
- PAI vs UNCY Comparison
PAI vs UNCY Comparison
Compare PAI & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAI
- UNCY
- Stock Information
- Founded
- PAI 1973
- UNCY 2016
- Country
- PAI United States
- UNCY United States
- Employees
- PAI N/A
- UNCY N/A
- Industry
- PAI Trusts Except Educational Religious and Charitable
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- PAI Finance
- UNCY Health Care
- Exchange
- PAI Nasdaq
- UNCY Nasdaq
- Market Cap
- PAI 118.3M
- UNCY 121.9M
- IPO Year
- PAI N/A
- UNCY 2021
- Fundamental
- Price
- PAI $12.29
- UNCY $5.33
- Analyst Decision
- PAI
- UNCY Strong Buy
- Analyst Count
- PAI 0
- UNCY 5
- Target Price
- PAI N/A
- UNCY $41.60
- AVG Volume (30 Days)
- PAI 25.0K
- UNCY 569.4K
- Earning Date
- PAI 01-01-0001
- UNCY 11-12-2025
- Dividend Yield
- PAI 4.78%
- UNCY N/A
- EPS Growth
- PAI N/A
- UNCY N/A
- EPS
- PAI N/A
- UNCY N/A
- Revenue
- PAI N/A
- UNCY N/A
- Revenue This Year
- PAI N/A
- UNCY N/A
- Revenue Next Year
- PAI N/A
- UNCY $19,392.60
- P/E Ratio
- PAI N/A
- UNCY N/A
- Revenue Growth
- PAI N/A
- UNCY N/A
- 52 Week Low
- PAI $10.59
- UNCY $3.71
- 52 Week High
- PAI $12.63
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- PAI 31.72
- UNCY 56.02
- Support Level
- PAI $12.41
- UNCY $4.28
- Resistance Level
- PAI $12.55
- UNCY $6.04
- Average True Range (ATR)
- PAI 0.11
- UNCY 0.41
- MACD
- PAI -0.01
- UNCY 0.07
- Stochastic Oscillator
- PAI 5.03
- UNCY 57.07
About PAI Western Asset Investment Grade Income Fund Inc.
Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. The company designed as a long-term investment and not as a trading vehicle. The fund seeks a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. Its portfolio is invested in securities which may be convertible into or exchangeable for, or carry warrants to purchase, common stock or other equity interests; and preferred stock.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.